The global bronchial biopsy devices market is anticipated to grow at a CAGR of 7.4% during the forecast period (2024-2031). Consistent FDA approval and continuous financial support are key drivers fostering growth in the bronchial biopsy devices market. The constant FDA approval attributes adherence to rigorous regulatory standards, instilling confidence in the safety and efficacy of these devices. In January 2023, Micronoma, INC., obtained FDA breakthrough device designation for OncobiotaLUNG, a novel liquid biopsy assay for lung carcinoma detection. OncobiotaLUNG is a minimally-invasive liquid biopsy analyzing tumor DNA and proteins in 500 ?l of plasma, eliminating the need for tissue biopsy. It categorizes pulmonary nodules into high risk and low risk, guiding physicians in tailored management prompt follow-up for high-risk nodules and adherence to guidelines for low-risk nodules. In recent years, technical advancements in endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) bronchial biopsy have significantly improved diagnostic capabilities and procedural efficiency. In October 2023, Praxis Medical secured 510(k) clearance from the US Food and Drug Administration (FDA) for its EndoCore Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) fine needle biopsy device. The EndoCore EBUS-TBNA biopsy device is designed for the diagnosis and staging of lung cancer and involves the insertion of a long, flexible tiny needle through a bronchoscope to perform a biopsy and pathological analysis.
Browse the full report description of “Bronchial Biopsy Devices Market Size, Share & Trends Analysis Report by Product (Biopsy Forceps, Transbronchial Needle Aspiration (Tbna) Needles, and Cytology Brushes), and by End-Use (Hospitals, Diagnostic Imaging Centers, Research and Academic Institutes, and Others), Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/bronchial-biopsy-devices-market
Further, the growing emergence of more front-line devices such as liquid biopsy are also contributing to the market growth. Liquid biopsy is minimally invasive, typically requiring a blood sample, avoiding the need for traditional tissue biopsies. For instance, in August 2020, Guardant Health, Inc., received US Food and Drug Administration approval on the Guardant360 CDx, the first liquid biopsy companion diagnostic that also used next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies NGS and liquid biopsy in one diagnostic test in order to guide treatment decisions.
Market Coverage
• The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Product
o By End user
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Becton, Dickinson, and Co., Cook Medical Inc., CONMED Corp., and Medtronic plc, among others.
Key questions addressed by the report
Global Bronchial Biopsy Devices Market Report Segment
By Product
By End-Use
Global Bronchial Biopsy Devices Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bronchial-biopsy-devices-market